ArticleFrontiers in microbiology2024
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Beyond probiotics and pathobionts: mechanistic roles of enterococcus-derived bioactive components in health and disease.Folia microbiologica · 2026Review
- Lactiplantibacillus plantarum: Systems Biology of a Versatile Microbe.Probiotics and antimicrobial proteins · 2026Review
- Effect of Limosilactobacillus reuteri SBC5-3 Cell-free Supernatant on Growth Performance, Intestinal Inflammation, and Microbiota in Weaned Piglets Challenged With Enterotoxigenic Escherichia coli K88.Probiotics and antimicrobial proteins · 2026Article
- Taraxacum alleviates ulcerative colitis, accompanied by the modulation of gut microbiota and restoration of intestinal barrier integrity.Frontiers in cellular and infection microbiology · 2026Article
- Microbial exopolysaccharides as bioactive modulators of intestinal health: a systematic review.Frontiers in nutrition · 2026Review
- Gut-Protective and Multifunctional Exopolysaccharide fromNutrients · 2025Article
- Genomic and Transcriptomic Dissection of Growth Characteristics and Exopolysaccharide-Related Bioactivities inFoods (Basel, Switzerland) · 2025Article
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Strain-Specific Therapeutic Potential ofNutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of inflammatory bowel disease (IBD), a common chronic intestinal disease, by exopolysaccharides (EPSs) produced by lactic acid bacteria has raised increasing concerns. Here, the EPS produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.